Point-of-care testing can achieve same-day diagnosis for infants and rapid ART initiation: results from government programmes across six African countries

Caroline E Boeke1,*, Jessica Joseph1,*, Melody Wang1, Zelalem M Abate2, Charles Atem3, Khady Diatou Coulibaly4, Adisu Kebede5, Brianán Kiernan6, Leonard Kingwara7,8, Phibeon Mangwendeza9, Tatenda Maparo9, Rose Nadege Mbaye6, Solomon Mukununguwa10, Catherine Ngugi18, Divine Nzuobontane3, Marie Claire Okomo Assoumou11, Yemsirach Reta5, Barbara Wambugu8, Maria R Rioja1, Trevor Peter1, Naoko Doi1, Lara Vojnov1, Shaukat Khan1,§ and Jilian A Sacks1

*Corresponding author: Shaukat Khan, 383 Dorchester Avenue, Suite 400, Boston, Massachusetts 02127, USA. Tel: +1-857-324-9852. (skhan@clintonhealthaccess.org)

*These authors contributed equally.

Abstract

Introduction: Point-of-care (POC) early infant diagnosis (EID) testing has been shown to dramatically decrease turnaround times from sample collection to caregiver result receipt and time to ART initiation for HIV-positive infants compared to centralized laboratory testing. As governments in sub-Saharan Africa implement POC EID technologies, we report on the feasibility and effectiveness of POC EID testing and the impact of same-day result delivery on rapid ART initiation within national programmes across six countries.

Methods: This pre-/post-evaluation compared centralized laboratory-based (pre) with POC (post) EID testing in 52 facilities across Cameroon, Democratic Republic of Congo, Ethiopia, Kenya, Senegal and Zimbabwe between April 2017 and October 2019 (country-dependent). Data were collected retrospectively from routine records at health facilities for all infants tested under two years of age. Hazard ratios and 95% confidence intervals were calculated to compare time-to-event outcomes, visualized with Kaplan–Meier curves, and the Somers’ D test was used to compare continuous outcomes.

Results: Data were collected for 2892 EID tests conducted on centralized laboratory-based platforms and 4610 EID tests on POC devices with 127 (4%) and 192 (4%) HIV-positive infants identified, respectively. POC EID significantly reduced the time from sample collection to caregiver result receipt (POC median: 0 days, IQR: 0 to 0 vs. centralized: 35 days, IQR: 26 to 56) and time from sample collection to ART initiation for HIV-positive infants (POC median: 1 day, IQR: 0 to 7 vs. centralized: 39 days, IQR: 26 to 57). With POC testing, 72% of infants received results on the same day as sample collection; HIV-positive infants with a same-day diagnosis had six times the rate of ART initiation compared to those diagnosed one or more days after sample collection (HR: 6.39; 95% CI: 3.44 to 11.85).

Conclusions: Same-day diagnosis and treatment initiation for infants is possible with POC EID within routine government-led and -supported public sector healthcare facilities in resource-limited settings. Given that POC EID allows for rapid ART initiation, aligning to the World Health Organization’s recommendation of ART initiation within seven days, its use in public sector programmes has the potential to reduce overall mortality for infants with HIV through early treatment initiation.

Keywords: point of care; early infant diagnosis; Africa; ART initiation; turnaround times

Additional information may be found under the Supporting Information tab for this article.
demonstrated POC testing leads to faster receipt of test results by caregivers and faster ART initiation [4-9]. As such, the 2016 WHO Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommends immediate implementation of POC EID. However, the real-world impact of POC EID on same-day diagnosis and rapid treatment initiation within decentralized national programmes in sub-Saharan Africa is still unclear.

Across 52 public sector facilities in six countries, a pre-/post-evaluation was conducted to assess differences in clinic receipt of test results, caregiver receipt of test results and test turnaround times comparing POC EID to centralized EID testing. Secondary analysis included differences in ART initiation and turnaround times. Within the POC arm, an additional secondary analysis was conducted to compare time to ART initiation for infants when caregivers received results on the same day as sample collection versus during subsequent clinic visits, one or more days later. This study is the first of its kind to evaluate large-scale implementation of POC EID in government-supported public health facilities.

2 | METHODS

2.1 | Study design

In this evaluation of routine programmatic implementation of POC EID, quality of EID service delivery and clinical outcomes were compared for centralized laboratory-based EID testing and POC EID testing at 52 public sector health facilities across six countries: Cameroon, Democratic Republic of Congo (DRC), Ethiopia, Kenya, Senegal and Zimbabwe. In 33 sites, Xpert® HIV-1 Qual assays were provided for diagnosis of HIV infection on existing Cepheid GeneXpert devices (Cepheid, Sunnyvale, CA, USA). The remaining 19 sites all used m-PIMA HIV-1/2 Detect assays on Abbott m-PIMA devices (Abbott, Chicago, IL, USA). In Cameroon and Senegal, all the m-PIMA devices were newly placed at the facility; in Zimbabwe, four devices were newly placed, four sites had existing m-PIMA devices and three sites had additional new m-PIMA devices placed in other wards apart from the HIV clinic, that is alternative entry points. The study aimed to compare a six-month time period in the same facilities before and after POC implementation, although due to logistical constraints in some countries the actual timeframes varied from three to nine months, with data collected between April 2017-October 2019 (country-dependent, see Table 1). For all countries except Ethiopia, the pre-implementation period was exactly one year prior to POC implementation. Sites in DRC and several sites in Senegal did not have centralized testing data available for comparison due to sporadic or poor access to the centralized laboratory and limited documentation of EID tests, but were included in POC-only analyses. No facilities received support from implementing partners for POC EID.

2.2 | Patient and site selection

National guidelines dictated eligibility for EID testing, which typically followed the 2015 WHO HIV Testing Guidelines [10]. These guidelines state that infants should be tested at four to six weeks and nine months, or at any point when exhibiting signs or symptoms suggestive of HIV infection. Although global guidance recommends virological testing up to aged 18 months, several national guidelines stipulate that infants can be tested up to 24 months of age due to prolonged breast-feeding periods. The study cohort included infants who were known to be exposed to HIV, and excluded infants greater than 24 months of age, already known HIV-positive, or too sick to be tested. If infants happened to be tested twice during either time period, only their first valid test record was included.

POC device placement for initial implementation in each country was determined by Ministries of Health based on infrastructure, human resource availability, existing POC device placement and utilization rates and annual patient volumes. For this evaluation, all implementing facilities were included except in Kenya, where only the first four sites were included in the evaluation.

2.3 | Implementation of POC EID testing

Implementation included training health facility staff on operational procedures for testing, clinical utilization of test results, documentation, device maintenance and quality control by national reference laboratory staff. Cartridges were supplied for POC tests. Supportive supervision visits were conducted throughout the implementation period to monitor activities, ensure enough staff were trained and troubleshoot any challenges with POC devices. The existing staff conducted all activities associated with POC testing.

GeneXpert devices in health facilities across all countries were already being used for TB testing in the onsite laboratory and were operated by laboratory staff, whereas m-PIMA devices were placed in the onsite laboratory in Cameroon and Senegal. In Zimbabwe, m-PIMA devices were either placed in the clinic, in antenatal, maternity, paediatric and/or outpatient wards, or in the on-site laboratory. As a result, Zimbabwe’s facilities had a wider variety of health cadres operating POC devices, including nurses and trained diagnostic assistants in the wards. Testing was done according to specific device manufacturers’ instructions. All facilities used whole blood as a sample type for GeneXpert and m-PIMA. In laboratories where GeneXpert was used for multiple test types, for example EID and TB, prioritization of tests was at the discretion of laboratory staff; in most facilities, EID samples were prioritized due to this test being the most time sensitive.

2.4 | Data collection and analysis procedures

Trained data collectors retrospectively extracted demographic, service delivery and clinical data from national and facility-specific laboratory and clinic registers as well as patient charts; data were captured electronically via SurveyCTO (2016 Dobility, Inc., Cambridge, MA, USA). Data collection for both centralized and POC EID outcomes allowed for each infant to have a follow-up period of 90 days, to allow for complete documentation in facility registers of testing and, for those who tested HIV-positive, treatment outcomes. In Senegal, due to logistical constraints, 20 infants tested on m-PIMA only had 30 days of follow-up, not the full 90 days.

The World Health Organization (WHO) recommends that results are returned to the caregiver as soon as possible, no
| Study Country | Number of Facilities | Study Design | Site Selection | POC Device Placement | Device | Time Frame: Pre | Time Frame: Post | # of Months per Time Segment |
|---------------|----------------------|--------------|----------------|----------------------|--------|---------------|----------------|--------------------------|
| Cameroon-1     | 3                    | Pre/post     | All facilities running EID tests on GX | Existing devices | GX     | Jul to Dec 2017 | Apr to Sep 2018 | 6                        |
| Cameroon-2     | 4                    | Pre/post     | All facilities running EID tests on GX | Existing devices | GX     | Apr to Sep 2018 | Apr to Sep 2018 | 8                        |
| DRC           | 9                    | Pre/post     | All facilities running EID tests on GX | Existing devices | GX     | Apr to Sep 2017 | Jul to Dec 2018  | 6                        |
| Ethiopia      | 4                    | Pre/post     | All facilities running EID tests on GX | Existing devices | GX     | May to Jul 2019 | May to Jul 2019 | 4                        |
| Kenya         | 9                    | Pre/post     | All facilities running EID tests on GX | Existing devices | GX     | May to Jul 2018 | May to Jul 2018 | 3                        |
| Senegal-1      | 4                    | Pre/post     | All facilities running EID tests on GX | Existing devices | GX     | Jul to Dec 2017 | Apr to Sep 2018 | 6                        |
| Senegal-2      | 9                    | Pre/post     | All facilities running EID tests on GX | Existing devices | GX     | Apr to Sep 2017 | Jul to Dec 2018  | 6                        |
| Zimbabwe-1     | 4                    | Pre/post     | All facilities running EID tests on GX | Existing devices | m-PIMA | Jul to Dec 2017 | Apr to Sep 2018 | 6                        |
| Zimbabwe-2     | 1                    | Pre/post     | All facilities running EID tests on GX | Existing devices | m-PIMA | Apr to Sep 2018 | Apr to Sep 2018 | 6                        |
more than 28 days after sample collection [11]. Therefore, the primary outcome was the proportion of test results received by caregiver within 28 days of sample collection. Caregiver receipt of results within the same day, seven and ninety days was also analysed. The WHO also recommends rapid ART initiation, defined as ART initiation within seven days of diagnosis, for HIV-positive children under five years [12]. Thus, the proportion of infants initiating ART within the same day and seven, twenty-eight and ninety days of sample collection was also analysed for HIV-positive infants, as were turnaround times between steps in the cascade of care. Finally, among infants tested with POC devices, median time from sample collection to ART initiation was compared between infants receiving a positive diagnosis on the same day as sample collection versus at least one day or more after sample collection.

Statistical analysis was performed using Stata SE 15 (StataCorp, TX, USA) and limited to infants with a valid test result (invalid or missing test results were excluded), as well as to those facilities with both POC and centralized testing data. Patients with missing dates for steps in the cascade of care were considered as failing to complete that step during analysis. Testing characteristics were presented as numbers and proportions for categorical variables and median and interquartile range (IQR) for continuous variables. The Somers’ D test was used to compare continuous outcomes (i.e. turnaround times) for centralized versus POC testing, to account for facility-level clustering. Time-to-event analyses were conducted with comparisons between centralized and POC testing, visually displayed in Kaplan–Meier curves, and through calculation of hazard ratios and 95% confidence intervals using maximum likelihood estimation and parametric regression survival-time models, as the proportional hazards assumption was not met. Shared frailties [13] were utilized to account for facility-level clustering and country was adjusted for as a covariate in the model. Statistical significance was defined as $p < 0.05$.

2.5 | Ethical approvals

Approval for this study was obtained from a local Institutional Review Board in each country (Cameroon: Comite National D’Ethique de la Recherche Pour La Sante Humaine 2018/06/1041/CE/CNERSH/SP; Democratic Republic of Congo: Université de Kinshasa École de Sante Publique Comite D’Ethique ESP/CE/079/2019; Ethiopia: Ethiopian Public Health Institute; EPHI-IRB-060-2017; Kenya: Kenyatta National Hospital-University of Nairobi Ethics & Research Committee P197/03/2018; Senegal: Republique du Senegal Ministere de la Sante et de L’Action Sociale 269MSAS/DGS/DLM/DLSI; Zimbabwe: Medical Research Council of Zimbabwe MRCZ/A/2470) and Advarra Institutional Review Board in the United States (#Pro000252217). Written informed consent was waived as data were collected retrospectively and all clinical elements (i.e. EID testing) followed standard of care practice.

3 | RESULTS

Patient and facility characteristics are described in Table 2 (disaggregated by country in Table S1). Overall, 4610 POC

| Table 2. Characteristics of infants receiving EID testing |
|----------------|----------------|----------------|
|                  | Centralized          | POC             |
|                  | n | %/median (IQR) | n | %/median (IQR) |
| Total tests      | 2892 | 100%          | 4610 | 100%          |
| Country/study    |     |                |     |                |
| Cameroon-1       | 160 | 6%            | 197 | 4%            |
| Cameroon-2       | 191 | 6%            | 315 | 7%            |
| DRC              | NA | NA            | 49  | 1%            |
| Ethiopia         | 143 | 5%            | 136 | 3%            |
| Kenya            | 186 | 6%            | 76  | 2%            |
| Senegal-1        | NA | NA            | 18  | 0%            |
| Senegal-2        | 12  | 0%            | 53  | 1%            |
| Zimbabwe-1       | 488 | 17%           | 668 | 14%           |
| Zimbabwe-2       | 1712 | 59%          | 3098 | 67%          |
| Infant age (days)|     |                |     |                |
| 0 to 2 months    | 2186 | 76%          | 3333 | 72%          |
| 3 to 8 months    | 489  | 17%           | 847  | 18%           |
| 9 to 18 months   | 179  | 6%            | 329  | 7%            |
| 19 to 24 months  | 8    | 0%            | 23   | 0%            |
| Infant sex       |     |                |     |                |
| Female           | 1200 | 41%          | 2327 | 50%          |
| Male             | 1332 | 46%          | 2206 | 48%          |
| Missing          | 360  | 12%           | 77   | 2%            |
| Test results     |     |                |     |                |
| Negative         | 2226 | 87%          | 4287 | 93%          |
| Positive         | 127  | 4%            | 192  | 4%            |
| Invalid/error    | 30   | 1%            | 94   | 2%            |
| Missing          | 209  | 7%            | 37   | 1%            |
| Entry point      |     |                |     |                |
| PMTCT/MCH        | 2481 | 86%          | 4072 | 88%          |
| Other            | 271  | 9%            | 500  | 11%           |
| Missing          | 140  | 5%            | 38   | 1%            |
| Device           |     |                |     |                |
| GeneXpert        | NA | NA            | 1144 | 25%          |
| m-PIMA           | NA | NA            | 3466 | 75%          |

EID, early infant diagnosis; IQR, interquartile range; NA, not applicable; PMTCT/MCH, prevention of mother-to-child transmission/maternal child health; POC, point-of-care.

EID and 2892 centralized laboratory-based EID tests were conducted of which 97% (4479) and 92% (2653) had valid test results respectively. Error rates were similar, with 2% of POC test results and 1% of centralized results being errors or invalid, but there were significantly fewer missing results for POC compared to centralized tests (1% vs. 7%). HIV positivity rate was 4% (192) for POC tests and 4% (127) for centralized tests. Overall, the median age of infants at sample collection was 45 (IQR: 35 to 64) days during the POC implementation and 46 (IQR: 42 to 58) days during centralized
testing, 50% of POC tests were among females as were 41% of centralized tests. Meanwhile, the median age of HIV-positive infants at sample collection was 149 days (IQR: 52 to 270) for infants tested on POC compared to 157 days (IQR: 64 to 267) with centralized testing.

The median turnaround time from sample collection to clinic receipt of result was same day (IQR: 0 to 0) with POC testing in comparison to 24 days (IQR: 14 to 36) with centralized testing. The median turnaround time to caregiver receipt also decreased to same day (IQR: 0 to 0) with POC testing from 35 days (IQR: 14 to 36) with centralized testing. The median time from sample collection to ART initiation was also significantly faster for POC (1 day; IQR: 0 to 7) compared to centralized testing (39 days; IQR: 26 to 57; Table 3).

Overall, HIV-positive infants who received a POC test result had an ART initiation rate more than six times faster than those who were diagnosed through centralized testing (HR: 6.74; 95% CI: 4.54 to 10.01; Table 3; Figure 1c). Within seven days after sample collection, 57% of infants who had tested positive with POC were initiated on treatment compared to 36% of infants who received their diagnosis on a subsequent day with POC. Forty-six percent of HIV-positive infants who received same-day diagnosis (caregiver receipt) initiated on ART on the day of sample collection. By seven days, 64% of same-day diagnosis infants initiated compared to 36% of infants whose caregivers received test results during a subsequent visit.

Outcomes were analysed separately for infants who received same-day diagnosis versus infants who received their diagnosis on a subsequent day with POC. Forty-six percent of HIV-positive infants who received same-day diagnosis (caregiver receipt) initiated on ART on the day of sample collection. By seven days, 64% of same-day diagnosis infants initiated compared to 36% of infants whose caregivers received test results during a subsequent visit. Overall, infants with a same-day diagnosis as sample collection had an ART initiation rate more than six times faster than those who received their diagnosis on a subsequent day (HR: 6.39; 95% CI: 3.44 to 11.85; Figure 2).

Table 3. Comparison of centralized laboratory and point-of-care early infant diagnosis on turnaround times and proportions from sample collection to clinic and caregiver receipt of results and ART initiation, with hazard ratios and 95% confidence intervals for time-to-event analyses

| Sample collection to clinic receipt | Centralized | POC | p-value | HR (95% CI) |
|-----------------------------------|-------------|-----|---------|-------------|
| Turnaround time (days)            | 1783 (24 (14 to 36)) | 4233 (0 (0 to 0)) | <0.001 | 13.83 (13.03 to 14.67) |
| Proportion result received same-day | 2653 (22 (1%)) | 4413 (3570 (81%)) | <0.001 |
| Proportion result received within 7 days | 2653 (155 (6%)) | 4413 (3982 (90%)) | <0.001 |
| Proportion result received within 28 days | 2653 (1111 (42%)) | 4413 (4142 (94%)) | <0.001 |
| Proportion result received within 90 days | 2653 (1783 (67%)) | 4413 (4229 (96%)) | <0.001 |

| Sample collection to caregiver receipt | Centralized | POC | p-value | HR (95% CI) |
|--------------------------------------|-------------|-----|---------|-------------|
| Turnaround time (days)               | 1543 (35 (26 to 56)) | 3902 (0 (0 to 0)) | <0.001 | 10.79 (10.12 to 11.50) |
| Proportion result received same-day   | 2653 (19 (1%)) | 4413 (3185 (72%)) | <0.001 |
| Proportion result received within 7 days | 2653 (35 (1%)) | 4413 (3547 (80%)) | <0.001 |
| Proportion result received within 28 days | 2653 (507 (19%)) | 4413 (3754 (85%)) | <0.001 |
| Proportion result received within 90 days | 2653 (1543 (58%)) | 4413 (3902 (88%)) | <0.001 |

| Sample collection to ART initiation, HIV + patients | Centralized | POC | p-value | HR (95% CI) |
|-----------------------------------------------------|-------------|-----|---------|-------------|
| Turnaround time (days)                              | 40 (39 (26 to 57)) | 142 (1 (0 to 7)) | <0.001 | 6.74 (4.54 to 10.01) |
| Proportion initiated on ART same-day                | 127 (2 (2%)) | 191 (65 (34%)) | 0.021 |
| Proportion initiated on ART within 7 days           | 127 (4 (3%)) | 191 (109 (57%)) | <0.001 |
| Proportion initiated on ART within 28 days          | 127 (13 (10%)) | 191 (128 (67%)) | <0.001 |
| Proportion initiated on ART within 90 days          | 127 (40 (31%)) | 191 (142 (74%)) | <0.001 |

ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; POC, point-of-care.

Facilities without centralized testing data from the pre-period were excluded from this analysis, as were test results that were errors, invalid or missing; Continuous turnaround time results are limited to those who received their results.
In this assessment of programme implementation across 52 public sector health facilities in six African countries, the use of POC EID testing significantly improved timeliness of clinic and caregiver receipt of results and subsequent ART initiation. Infants who received POC testing had an ART initiation rate more than six times faster than those who were diagnosed through centralized testing. In addition, in analyses limited to HIV-positive infants tested on POC, receiving results on the same day as sample collection expedited rapid ART initiation within seven days compared to infants whose caregivers received the diagnosis on subsequent days. This study adds important implementation knowledge and generalizable results as it was conducted within the existing public health system across six countries with mature and nascent centralized laboratory systems.

These findings demonstrate a dramatic improvement in timely results delivery and rapid initiation of treatment for this vulnerable infant population in public health systems, consistent with previous studies showing benefits of POC EID [4,6-9]. Notably, a study in eight African countries from 2014 to 2017 reported that POC EID significantly reduced the median time to caregiver receipt of results from 55 to 0 days and the median time to ART initiation from 49 to 0 days [6]. The sites in this study were supported by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and thus results may not be generalizable to public-sector facilities; also, this study did not specifically look at the impact of same-day diagnosis on ART initiation rates. A cluster-randomized trial in Mozambique reported that POC EID significantly increased ART initiation within 60 days (89.7% vs. 12.8% for centralized testing) and retention in care after 90 days (61.6% vs. 42.9%); the median time from sample collection to ART initiation was less than one day for the POC EID arm [4]. In a stepped-wedge trial in Kenya and Zimbabwe, POC EID significantly reduced time to caregiver receipt of results and ART initiation [7]. Finally, small feasibility studies in Malawi and Zimbabwe also reported turnaround times to ART initiation of one day or less with POC EID [8,9]. It is reassuring that in our large study across multiple public-sector contexts, similarly dramatic improvements were observed, including median turnaround times of 0 days for caregiver receipt of results and 1 day for ART initiation.

Our study demonstrates the positive impact of same-day result delivery on rapid ART initiation. In contrast to infants, children over two years of age and adults (tested using lateral

Figure 1. Kaplan–Meier curves and hazard ratios (95% confidence intervals) for time from sample collection to: (a) clinic receipt of results comparing POC EID testing and centralized EID testing; (b) caregiver receipt of results comparing POC EID testing and centralized EID testing; and (c) ART initiation comparing POC EID testing and centralized EID testing.

4 | DISCUSSION
flow, rapid diagnostic tests) receive HIV diagnosis on the same visit as when testing is performed, which then allows for same-day treatment initiation. Ideally, this should also be the case for infants who are at a higher risk of morbidity and mortality and would benefit from rapid ART initiation, translating to better health outcomes [14-16]. Instead, HIV diagnosis for infants was observed to take closer to 28 days with centralized laboratory testing. It is also important to consider the time and cost savings to the caregiver from being able to receive results and initiate an infant on ART in a single day versus having to make multiple trips to the facility for each of these steps. In our study, 46% of infants with same-day diagnosis initiated on ART the same day thus completing the cascade of care in one visit, and 64% of infants initiated within seven days, as recommended by the WHO. However, gaps in care remain. Only 74% of infants tested through POC ever initiated treatment, underscoring that POC testing may only be one part of the solution. This represents a missed opportunity to improve outcomes in positive infants and suggests that additional interventions outside of implementation of POC testing are needed to support EID programmes to ensure timely initiation of HIV-positive infants.

While we observed consistent improvements with POC EID across countries, some differences were observed in data from particular countries. First, Zimbabwe had larger testing volumes than other contexts due to a larger number of facilities in the country, the addition of birth testing to EID programmes, and some testing in alternate entry points. The primary difference we observed in POC outcomes was in Kenya, where the median turnaround time from sample collection to caregiver receipt of results (28 days) was substantially higher than in other countries, although this still represented a nearly two-week decrease compared to testing in the centralized laboratory. The median turnaround time from sample collection to clinic receipt of results was five days in Kenya; this indicates that most results were available at the facility within a week, yet caregivers did not return to collect them for several weeks. These values were higher than those reported in the stepped-wedge trial of POC EID in Kenya supported by EGPAF [7]. Unlike partner supported sites, there was not an active mechanism for result delivery to caregivers in the context of the public sector sites included in our analysis in Kenya, attenuating the impact of POC. These findings highlight the importance of appropriate programme messaging, clinical mentorship and active follow-up with patients to maximize the benefits of POC EID, which was noted previously when POC testing was piloted for at/near-birth testing in Kenya [17].

Additional considerations for governments considering POC EID testing programmes include feasibility and usability of the device, cost and cost-effectiveness. We observed relatively low error rates in this study (2% for POC, compared to 1% for centralized testing), which is reassuring in a real-world context. A qualitative study supported by EGPAF reported high levels of satisfaction with POC EID by healthcare workers and laboratory technicians, indicating that POC programmes would be feasible for the national scale [18]. While we do not present information on cost or cost-effectiveness in this analysis, a recent analysis in Zimbabwe concluded that POC EID testing is likely to be cost-effective [19] and that benefits will be greater by investing in POC EID compared to strengthening centralized laboratory networks [20,21]. Additionally, a time-motion study in Zimbabwe noted that POC did not require additional human resource time versus sending DBS samples for EID testing at a centralized laboratory [22]. Based on mounting evidence in support of POC EID, governments across sub-Saharan Africa are scaling up POC EID more broadly, with the Ministry of Health of Malawi adopting a policy of providing POC EID testing for all infants.

This evaluation has several limitations, most notably the fact that the study design was not a randomized controlled trial; utilizing a pre/post design meant that other factors, especially those that change over time, could have influenced the outcomes. Testing volumes could not be directly compared for POC versus centralized testing, as some sites had additional testing conducted in the implementation period. A clinical refresher training occurred as part of POC implementation, which did not happen before the lab-based timeline and could have impacted results. Additionally, while every attempt was made to ensure that the data included was of high quality, as data were captured through routine care, some facilities had large amounts of missing data points, often due to a lack of
documentation and poor record keeping. Varying sample sizes in testing volumes across the countries meant that some countries influenced the results more than others (e.g., Zimbabwe contributed 79% of all testing data) and country-specific analyses could not be conducted in all settings, especially those with very small numbers. Another limitation was that we assessed data from 90 days after sample collection, but ART initiation may have occurred after this timeframe in some cases, so we did not capture visit dates beyond ART initiation, and therefore could not examine retention in care. Finally, in the analysis comparing same-day diagnosis and diagnosis on a subsequent visit, immortal time bias may be present.

5 | CONCLUSIONS

These findings support the implementation of POC EID in routine government-supported public sector healthcare facilities in resource-limited settings to provide same-day test results and treatment initiation for infants. Given the large number of infants tested across 52 facilities in six countries, findings may be generalizable to other similar programmes at facilities in sub-Saharan Africa. While there may be some implementation challenges that need to be addressed and areas for continued improvement and support, POC EID has been demonstrated to dramatically reduce time to results delivery to infant caregivers and infant initiation on treatment, which will likely translate to improvements in infant survival. Most importantly, data shows same-day diagnosis is achievable in a public health context and leads to a faster rate of ART initiation thus supporting the broader use of POC testing for EID.

AUTHORS’ AFFILIATIONS

1 Clinton Health Access Initiative, Boston, MA, USA; 2 Clinton Health Access Initiative, Addis Ababa, Ethiopia; 3 Clinton Health Access Initiative, Yaoundé, Cameroon; 4 Division de la Lutte Contre le SIDA et les IST, Ministère de la Santé et de l’Action Sociale, Dakar, Senegal; 5 Ethiopian Public Health Institute, Addis Ababa, Ethiopia; 6 Clinton Health Access Initiative, Dakar, Senegal; 7 National HIV Reference Lab, Nairobi, Kenya; 8 National AIDS and STI Control Programme (NASCOP), Nairobi, Kenya; 9 Clinton Health Access Initiative, Harare, Zimbabwe; 10 Ministry of Health and Child Care, Harare, Zimbabwe; 11 National Public Health Laboratory, Yaoundé, Cameroon

COMPETING INTERESTS

The authors declare no competing interests.

ACKNOWLEDGEMENTS

We gratefully acknowledge the patients, healthcare providers and teams from the government and Clinton Health Access Initiative who contributed to this project. This project was made possible thanks to Unitaid’s support. The funder had no role in the design or implementation of this study. We also acknowledge the Ethiopian Public Health Institute, Therese Nduwimana and Muluh Clifford from UNICEF Cameroon, Zeh Kakanou and Abobo Abessolo Stephanie from the Ministry of Health, Cameroon, Makage Elungnde from CHAI Cameroon, Dr. Angela Mushavi from the Ministry of Health and Child Care Zimbabwe and Evidence Makadzange from CHAI Zimbabwe.

REFERENCES

1. UNAIDS. AIDSinfo 2019 data [Early Infant Diagnosis - Global]. Available from: http://aidsinfo.unaids.org.
2. UNAIDS. On the fast-track to an AIDS-free generation. 2016.
3. Jani IV, Meggi B, Mabunda N, Vubil A, Sitoe NE, Tobaiwa O, et al. Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test. J Acquir Immune Defic Syndr. 2014;67(1):e1–4.
4. Jani IV, Meggi B, Loqila O, Tobaiwa O, Mudenyangia C, Zitha A, et al. Effect of point-of-care early infant diagnosis on antiretroviral therapy initiation and retention of patients. AIDS. 2018;32(11):1453–61.
5. Agutu CA, Ngetsa CJ, Price MA, Rineke de Wit TF, Omosa-Manyaky G, Sanders EJ, et al. Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care. PLoS One. 2019;14:e0218369.
6. Bianchi F, Cohn J, Sacks E, Bailey R, Lemaire J-F, Machekano R, et al. Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: an observational study in eight African countries. Lancet HIV. 2019;6(6):e373–81.
7. Sacks E, Cohn J, Ochuka B, Mafaune H, Chadambuka A, Odhiambo C, et al. Impact of routine point-of-care versus laboratory testing for early infant diagnosis of HIV: results from a multicountry stepped-wedge cluster-randomized controlled trial. J Acquir Immune Defic Syndr. 2020;84 Suppl 1:S35–11.
8. Ndlovu Z, Fajardo E, Mbofana E, Mbofana E, Maparo T, Garone D, et al. Multidisease testing for HIV and TB using the GeneXpert platform: a feasibility study in rural Zimbabwe. PLoS One. 2018;13:e0193577.
9. Mwenda R, Fong Y, Magombo T, Saka E, Mlidiyan D, Mwase C, et al. Significant patient impact observed upon implementation of point-of-care early infant diagnosis technologies in an observational study in Malawi. Clin Infect Dis. 2018;67(5):701–7.
10. WHO. Consolidated guidelines on HIV testing services. Geneva: World Health Organization (WHO); 2015.
11. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Geneva: World Health Organization (WHO); 2016.
12. Organization WH. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy, July 2017. Geneva: Organization WH; 2017.
13. Balan TA, Putter H. A tutorial on frailty models. Stat Methods Med Res. 2020;29(11):3424–54.
14. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Medicine. 2011;8:e1001056.
15. Amanyire G, Semtala FC, Namusobya J, Katuramu R, Kampiire L, Wallenti J, et al. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV. 2016;3(11):e539–48.
16. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomised controlled trial. PLoS Medicine. 2016;13:e1002015.
17. Wexler C, Nazir N, Maloba M, Brown M, Gojkin K, Gauthrey E, et al. Programmatic evaluation of feasibility and efficiency of at birth and 6-week point of care HIV testing in Kenyan infant. PLoS One. 2020;15:e0240621.
18. Bianchi F, Clemens S, Arif Z, Sacks E, Cohn J, EGPAF POC EID Study team. Acceptability of routine point-of-care early infant diagnosis in eight African Countries: Findings from a qualitative assessment of clinical and laboratory personnel. J Acquir Immune Defic Syndr. 2020;84 Suppl 1:S41–9.
19. Frank SC, Cohn J, Dunning L, Sacks E, Walensky RP, Mukherjee S, et al. Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. Lancet HIV. 2019;6(3):e182–90.
20. McCann NC, Cohn J, Flanagan C, Sacks E, Mukherjee S, Walensky RP, et al. Strengthening existing laboratory-based systems vs. investing in point-of-care assays for early infant diagnosis of HIV: a model-based cost-effectiveness analysis. J Acquir Immune Defic Syndr. 2020;84 Suppl 1:S12–21.
21. Salvatore PP, de Broucker G, Vojnov L, Moss WJ, Dowdy DW, Sutcliffe CG. Modeling the cost-effectiveness of point-of-care platforms for infant diagnosis of HIV in sub-Saharan African countries. AIDS. 2021;35(2):287–97.
22. Adebutun O, Mukherjee S, Sacks E, Ciarencio A, Chadambuka A, Mafaune H, et al. Front-line human resource time-use for early infant HIV diagnosis: a comparative time-motion study at centralized and point-of-care health facilities in Zimbabwe. J Acquir Immune Defic Syndr. 2020;84 Suppl 1:S70–7.
SUPPORTING INFORMATION

Additional information may be found under the Supporting Information tab for this article.

**Table S1.** Characteristics of infants receiving EID testing by country

**Table S2.** Comparison of centralized laboratory and point-of-care early infant diagnosis on turnaround times from sample collection to clinic and caregiver receipt and ART initiation, by country